WESTMINSTER, Colo.--(BUSINESS WIRE)--Nov. 10, 2009-- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics, today announced that management will present at two upcoming conferences: the Lazard Capital Markets 6th Annual Healthcare Conference and the Windhover Therapeutic Area Partnerships event, where the Company’s Pralatrexate for Peripheral T-cell Lymphoma project was named as one of Windhover’s Top 10 interesting oncology projects. Details are as follows:

There will be a live webcast of the Lazard Capital Markets presentation, which will be accessible through a link posted on the “Investors - Presentations and Events” section of the Company’s website at www.allos.com. The webcast will be available for replay for two weeks.

About Allos Therapeutics

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN^TM (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. Allos is headquartered in Westminster, CO. For additional information, please visit www.allos.com.

Safe Harbor Statement

The anticipated presentations will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentations. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of these presentations, except as required by law.

Source: Allos Therapeutics

Allos Therapeutics
Monique Greer, 720-540-5268
mgreer@allos.com